Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

JA Maynard, CBM Maassen, SH Leppla, K Brasky… - Nature …, 2002 - nature.com
JA Maynard, CBM Maassen, SH Leppla, K Brasky, JL Patterson, BL Iverson, G Georgiou
Nature biotechnology, 2002nature.com
The tripartite toxin produced by Bacillus anthracis is the key determinant in the etiology of
anthrax. We have engineered a panel of toxin-neutralizing antibodies, including single-
chain variable fragments (scFvs) and scFvs fused to a human constant κ domain (scAbs),
that bind to the protective antigen subunit of the toxin with equilibrium dissociation constants
(K d) between 63 nM and 0.25 nM. The entire antibody panel showed high serum, thermal,
and denaturant stability. In vitro, post-challenge protection of macrophages from the action of …
Abstract
The tripartite toxin produced by Bacillus anthracis is the key determinant in the etiology of anthrax. We have engineered a panel of toxin-neutralizing antibodies, including single-chain variable fragments (scFvs) and scFvs fused to a human constant κ domain (scAbs), that bind to the protective antigen subunit of the toxin with equilibrium dissociation constants (Kd) between 63 nM and 0.25 nM. The entire antibody panel showed high serum, thermal, and denaturant stability. In vitro, post-challenge protection of macrophages from the action of the holotoxin correlated with the Kd of the scFv variants. Strong correlations among antibody construct affinity, serum half-life, and protection were also observed in a rat model of toxin challenge. High-affinity toxin-neutralizing antibodies may be of therapeutic value for alleviating the symptoms of anthrax toxin in infected individuals and for medium-term prophylaxis to infection.
nature.com